Literature DB >> 620266

Thyroid function in lung cancer.

J G Ratcliffe, B H Stack, R W Burt, W A Radcliffe, W G Spilg, J Cuthbert, R S Kennedy.   

Abstract

Thyroid function was assessed at the time of initial diagnosis in 204 patients with lung cancer and compared with that of age and sex-matched patients with non-malignant lung disease. Abnormalities in thyroid function were found in 67 patients (33%). The most prevalent abnormality was a low T3 concentration; this was not associated with other clinical or biochemical evidence of hypothyroidism, but the short-term prognosis of these patients was worse than that of matched patients with lung cancer having normal T3 concentrations. Primary hypothyroidism occurred in three patients, low T4 concentrations and free thyroxine index (FTI) with normal thyrotrophin (TSH) concentrations in four patients, and moderately raised TSH with normal thyroid hormone concentrations in six patients; nine patients had a raised FTI with or without raised T4 concentration as the sole abnormality.Overall, the pattern of thyroid hormone metabolism in lung cancer was a tendency towards reduced T3 concentrations with significantly increased T4/T3 ratios and modestly increased 3,3',5'-triiodothyronine (rT3) concentrations. The altered T4/T3 ratio was particularly noticeable in patients with anaplastic tumours of small ("oat cell") and large cell types, but was not apparently related to detectable extrathoracic metastases.These data suggest that thyroid hormone metabolism is altered in patients with lung cancer by decreased 5'-monodeiodination of T4. The resulting low T3 concentrations and altered T4/T3 ratio may be partly responsible for the reduced ratio of androsterone to aetiocholanolone observed in lung cancer, which is known to be a poor prognostic sign.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620266      PMCID: PMC1602576          DOI: 10.1136/bmj.1.6107.210

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  10 in total

1.  [Paraneoplastic endocrine syndromes. II. Hyperthyroidism and various endocrinopathies].

Authors:  H BRICAIRE; J LEPRAT
Journal:  Presse Med       Date:  1962-10-27       Impact factor: 1.228

2.  The radioimmunoassay of 3,3',5' - triiodothyronine (reverse T3) in unextracted human serum.

Authors:  W A Ratcliffe; J Marshall; J G Ratcliffe
Journal:  Clin Endocrinol (Oxf)       Date:  1976-11       Impact factor: 3.478

3.  Paraneoplastic syndromes. Hyperadrenocorticism and ACTH-releasing factor.

Authors:  T T Amatruda; G V Upton
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

4.  Discriminant function based on steroid abnormalities in patients with lung cancer.

Authors:  L G Rao
Journal:  Lancet       Date:  1970-08-29       Impact factor: 79.321

5.  Thyroid status and breast cancer. Reappraisal of an old relationship.

Authors:  A R Moossa; D A Evans; A C Brewer
Journal:  Ann R Coll Surg Engl       Date:  1973-09       Impact factor: 1.891

6.  Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness.

Authors:  J N Carter; C J Eastmen; J M Corcoran; L Lazarus
Journal:  Clin Endocrinol (Oxf)       Date:  1976-11       Impact factor: 3.478

7.  Semi-automated radioimmunoassays for total serum thyroxine and triiodothyronine.

Authors:  G S Challand; W A Ratcliffe; J G Ratcliffe
Journal:  Clin Chim Acta       Date:  1975-04-02       Impact factor: 3.786

8.  Serum triiodothyronine and reverse triiodothyronine concentrations after surgical operation.

Authors:  W A Burr; E G Black; R S Griffiths; R Hoffenberg
Journal:  Lancet       Date:  1975-12-27       Impact factor: 79.321

9.  Is "T4 toxicosis" a normal biochemical finding in elderly women?

Authors:  K E Britton; V Quinn; S M Ellis; A C Cayley; J M Miralles; B L Brown; R P Ekins
Journal:  Lancet       Date:  1975-07-26       Impact factor: 79.321

10.  Radioimmunoassay of human serum thyrotrophin.

Authors:  R Hall; J Amos; B J Ormston
Journal:  Br Med J       Date:  1971-03-13
  10 in total
  4 in total

1.  Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study.

Authors:  Umut Dişel; Ayberk Beşen; Cemile Karadeniz; Hüseyin Mertsoylu; Ahmet Sezer; Fatih Köse; Ahmet TanerSümbül; Ozlem Gürkut; Sadik Muallaoğlu; Hüseyin Abali; Ozgür Ozyilkan
Journal:  Med Oncol       Date:  2012-05-22       Impact factor: 3.064

2.  Levothyroxine and lung cancer in females: the importance of oxidative stress.

Authors:  Umberto Cornelli; Gianni Belcaro; Martino Recchia; Annarosa Finco
Journal:  Reprod Biol Endocrinol       Date:  2013-08-08       Impact factor: 5.211

Review 3.  Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis.

Authors:  Yu-Chin Liu; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

Review 4.  The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research.

Authors:  Maria V Deligiorgi; Dimitrios T Trafalis
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.